A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

• Status: Completed
• Trial end date: 2020-12-01

Summary

A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: University of Ulm
• Collaborators: Anticancer Fund, Belgium; Reliable Cancer Therapies
• Treatments: Aprepitant; Auranofin; Captopril; Celecoxib; Dacarbazine; Disulfiram; Fosaprepitant; Hydroxyitraconazole; Itraconazole; Minocycline; Ritonavir; Sertraline; Temozolomide